SavedAdd your journal

Journals / Anatomy / 2019 / Cilt: 13 - Sayı: 3

Potential role of empagliflozin in prevention of nephropathy in streptozotocin-nicotinamideinduced type 2 diabetes: an ultrastructural study

Marwa Abd EL KADER
Hagar A. HASHİSH
Journal
Anatomy
Pages
137–148
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This effect could be related to reduction of hyperglycemia andimprovement of cellular defense mechanisms, and reduction of glucose-induced oxidative stress and autophagy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic nephropathy is a serious factor in end-stage renal disease worldwide.
📊
Key Findings & Data:Sodium-glucose cotransporter 2inhibitors, the most novel glucose-lowering drug, may have a nephroprotective effect by modulating blood glucose, bloodpressure and autophagy.
💡
Conclusion & Impact:This effect could be related to reduction of hyperglycemia andimprovement of cellular defense mechanisms, and reduction of glucose-induced oxidative stress and autophagy.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic nephropathy is a serious factor in end-stage renal disease worldwide. Sodium-glucose cotransporter 2inhibitors, the most novel glucose-lowering drug, may have a nephroprotective effect by modulating blood glucose, bloodpressure and autophagy. The present work aimed to study the possible protective effect of empagliflozin in Type 2 diabeticnephropathy with special considerations to oxidative stress, fibrosis and ultrastructural modulation including autophagy.Methods: Thirty-six adult male Sprague-Dawley rats were divided into 3 groups; control, diabetic, and treatment. Type 2 diabetes was induced by pretreatment with nicotinamide followed by single low-dose of streptozotocin (40 mg/kg, i.p). The treatment group received empagliflozin (10 mg/kg/day, intragastric) for 4 weeks. At the end of 4 weeks, parameters of renal function and oxidative stress were analyzed. Kidney samples were collected for histological and ultrastructural studies.Results: Empagliflozin significantly reduced hyperglycemia, blood urea nitrogen, serum creatinine and oxidative stress whichwere elevated in the diabetic group. It also decreased renal tissue injury and fibrosis; however, did not lower the increased kidney index and glomerular size. Beside the amelioration of ultrastructure changes, empagliflozin enhanced the autophagy in renaltubular cells, indicated by increased number of autophagic vacuoles.Conclusion: Empagliflozin provided an efficient, but not complete protection against diabetic nephropathy in streptozotocin-nicotinamide-induced type 2 diabetic rat model. This effect could be related to reduction of hyperglycemia andimprovement of cellular defense mechanisms, and reduction of glucose-induced oxidative stress and autophagy.

🔖

Cite This Article

KADER, M. A. E., HASHİSH, H. A. (2022). Potential role of empagliflozin in prevention of nephropathy in streptozotocin-nicotinamideinduced type 2 diabetes: an ultrastructural study. Anatomy, Cilt: 13 - Sayı: 3, 137–148. https://ajindex.com/articles/439447

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW. Nephropathy in diabetes. Diabetes Care 2004;27:79–83
  2. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010;6:319–30
  3. Liu WJ, Huang WF, Ye L, Chen RH, Yang C, Wu HL, Pan QJ, Liu HF. The activity and role of autophagy in the pathogenesis of diabetic nephropathy. Eur Rev Med Pharmaco 2018;22:3182–9
  4. Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Sango K, Utsunomiya K. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci 2017;18. pii: E1083
  5. Shen Z, Fang Y, Xing T, Wang F. Diabetic nephropathy: from pathophysiology to treatment. J Diabetes Res 2017;2379432
  6. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell 2011;146:682–95
  7. Gonzalez CD, Lee MS, Marchetti P, Pietropaolo M, Towns R, Vaccaro MI, Watada H, Wiley JW. The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy 2011;7:2–11
  8. Yang C, Kaushal V, Shah SV, Kaushal GP. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol 2008;294:F777–87
  9. Hartleben B, Godel M, Meyer-Schwesinger C, Liu S, Ulrich T, Kobler S, Wiech T, Grahammer F, Arnold SJ, Lindenmeyer MT, Cohen CD, Pavenstadt H, Kerjaschki D, Mizushima N, Shaw AS, Walz G, Huber TB. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010;120:1084–96
  10. Jung CH, Jang JE, Park JY. A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor. Diabetes Metab J 2014;38:261–73
  11. Syed SH, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M, Abbas A, Said S, Mukherjee D. A review of sodium glucose co-transporter inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc Hematol Agents Med Chem 2015;13:105–12
  12. Takakura S, Toyoshi T, Hayashizaki Y, Takasu T. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sci 2016;147:125–31
  13. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care 2016;39:165–71
  14. Miller EM. Elements for success in managing Type 2 diabetes with SGLT-2 inhibitors: role of the kidney in glucose homeostasis: implications for SGLT-2 inhibition in the treatment of type 2 diabet